This video supports improved clinical awareness and encourages comprehensive care strategies for patients living with both CRSwNP and asthma.

In this highlight video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Marjolein de-Bruin Weller discusses the latest real-world data on the effects of advanced systemic treatments in patients with AD.
In this video from EADV 2025, Professor Metz shares exciting data from therapies recently approved or in late-stage development for CSU.

In this clip from the April WCPD 2025 symposium, Dr Amy Paller highlights CCL17 (TARC) as an important biomarker in AD.
Join leading pulmonologists Drs. Njira Lugogo, Simon Couillard, and Mario Castro, as they explore the role of type 2 inflammation in the pathogenesis of mucus plugging in the airways, the burden of excess mucus in patients with moderate-to-severe asthma, and how reducing airway mucus may lead to improved long-term patient outcomes.
Dr. Lawrence Eichenfield discusses the meaning of "early intervention" and its potential implications in atopic dermatitis.

This cross-TA plenary session addressed challenges in type 2 inflammation-driven diseases. Esteemed faculty, including Profs Klaus Rabe, Sharon Dell, Anju Peters, Milli Gupta, Eric Simpson, Stella Lee, and moderator Oscar Palomares, discussed strategies to enhance quality of life, reduce disease burden, and prioritize patient-centered care.
Hear Dr. Lawrence Eichenfield share the recent consensus definitions from the International Eczema Council.
Dr. Lawrence Eichenfield shares the cumulative burdens faced by patients with atopic dermatitis.
Dr. Elena Netchiporouk illustrates key considerations for diagnosing CSU at EADV 2025.

In this highlight video from the September 2024 ADVENT symposium at EADV’s Annual Meeting in Amsterdam, the Netherlands, Dr. Eric Simpson explores potential considerations when discussing the concept of disease modification and how early intervention might be disease modifying in AD.